Organon & Co. (NYSE:OGN) Shares Up 5.7% - Time to Buy?

Organon & Co. (NYSE:OGN - Get Free Report) traded up 5.7% during mid-day trading on Tuesday . The stock traded as high as $15.95 and last traded at $15.95. Approximately 1,984,320 shares traded hands during mid-day trading, a decline of 29% from the average daily volume of 2,811,156 shares. The stock had previously closed at $15.08.

Wall Street Analysts Forecast Growth

OGN has been the subject of a number of recent analyst reports. Morgan Stanley lowered their price target on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research report on Friday, February 14th. TD Cowen raised Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Barclays cut their price target on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Organon & Co. has a consensus rating of "Hold" and a consensus target price of $20.80.

Organon & Co. Price Performance

The stock has a market cap of $3.84 billion, a P/E ratio of 4.48, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a 50-day moving average price of $15.44 and a 200-day moving average price of $17.14.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.51%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.'s dividend payout ratio is 33.63%.

Institutional Trading of Organon & Co.

A number of hedge funds have recently made changes to their positions in OGN. Prospera Private Wealth LLC bought a new stake in Organon & Co. in the third quarter worth $25,000. Horizon Bancorp Inc. IN grew its stake in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after acquiring an additional 1,585 shares during the period. Millstone Evans Group LLC purchased a new position in shares of Organon & Co. during the fourth quarter valued at approximately $29,000. Larson Financial Group LLC boosted its holdings in Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock worth $33,000 after purchasing an additional 1,734 shares during the last quarter. Finally, Riverview Trust Co grew its position in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock worth $36,000 after purchasing an additional 1,292 shares during the period. 77.43% of the stock is owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.